HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Peng, Bin ^a   Xu, Limin ^a   Cao, Fanfan ^a   Wei, Tingxuan ^a   Yang, Chunxin ^b   Uzan, Georges ^c   Zhang, Denghai ^a,c  

^a Shanghai Gongli Hospital   (China)

^b FUDAN UNIVERSITY   (China)

^c HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELASTROL; CELL CYCLE PROTEIN 37; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; THIOL DERIVATIVE; TRIPTERINE; TRITERPENE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN U937; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONOCYTIC LEUKEMIA; APOPTOSIS; CELL SEPARATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOPRECIPITATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL SEPARATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G0 PHASE; G1 PHASE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOPRECIPITATION; SULFHYDRYL COMPOUNDS; TRITERPENES; U937 CELLS;

EID: 77950818403     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-79     Document Type: Article

References (39)

1. Li Y, Zhang T, Schwartz SJ, Sun D. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat 2009, 12:17-27. 10.1016/j.drup.2008.12.002, 2692088, 19179103.
2. Amolins MW, Blagg BS. Natural product inhibitors of Hsp90: potential leads for drug discovery. Mini Rev Med Chem 2009, 9:140-152. 10.2174/138955709787316056, 2659174, 19200020.
3. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008, 13:38-43. 10.1016/j.drudis.2007.10.007, 18190862.
4. Chiosis G, Neckers L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol 2006, 1:279-284. 10.1021/cb600224w, 17163756.
5. Banerji U, Sain N, Sharp SY, Valenti M, Asad Y, Ruddle R, Raynaud F, Walton M, Eccles SA, Judson I, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol 2008, 62:769-778. 10.1007/s00280-007-0662-x, 18193424.
6. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008, 14:8302-8307. 10.1158/1078-0432.CCR-08-1002, 2629404, 19088048.
7. Tse AN, Klimstra DS, Gonen M, Shah M, Sheikh T, Sikorski R, Carvajal R, Mui J, Tipian C, O'Reilly E, et al. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 2008, 14:6704-6711. 10.1158/1078-0432.CCR-08-1006, 18927314.
8. Driggers EM, Hale SP, Lee J, Terrett NK. The exploration of macrocycles for drug discovery--an underexploited structural class. Nat Rev Drug Discov 2008, 7:608-624. 10.1038/nrd2590, 18591981.
9. Trott A, West JD, Klaic L, Westerheide SD, Silverman RB, Morimoto RI, Morano KA. Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol Biol Cell 2008, 19:1104-1112. 10.1091/mbc.E07-10-1004, 2262981, 18199679.
10. Kalmar B, Greensmith L. Activation of the heat shock response in a primary cellular model of motoneuron neurodegeneration-evidence for neuroprotective and neurotoxic effects. Cell Mol Biol Lett 2009, 14:319-335. 10.2478/s11658-009-0002-8, 19183864.
11. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006, 10:321-330. 10.1016/j.ccr.2006.09.005, 17010675.
12. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, Sun D, Roe SM. A novel H sp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008, 7:162-170.
13. Chang FR, Hayashi K, Chen IH, Liaw CC, Bastow KF, Nakanishi Y, Nozaki H, Cragg GM, Wu YC, Lee KH. Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii. J Nat Prod 2003, 66:1416-1420. 10.1021/np030241v, 14640511.
14. Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y, Sakato N. Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 2003, 67:1883-1887. 10.1271/bbb.67.1883, 14519971.
15. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006, 66:4758-4765. 10.1158/0008-5472.CAN-05-4529, 16651429.
16. Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 2008, 111:5654-5662. 10.1182/blood-2007-11-126003, 2424160, 18305216.
17. Srethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 2000, 60:3940-3946.
18. Georgakis GV, Li Y, Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 2006, 135:68-71. 10.1111/j.1365-2141.2006.06247.x, 16925576.
19. Harrison GM, Bennett AJ, Moody M, Read GF, Williams PE. Use of formalin-fixed, propidium iodide-stained human leukocytes as a standard for enumerating CD4+ T lymphocytes in a single-platform assay. Clin Diagn Lab Immunol 2001, 8:397-401. 96069, 11238228.
20. Cao FF, Xu LM, Peng B, Xie QH, Uzan G, Zhang DH. A routinely applicable way for using FCM in cell enumeration with CFSE-labeled CellBeads as internal standard. Cytometry A 2009, 75:975-978.
21. Sreeramulu S, Gande SL, Gobel M, Schwalbe H. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed Engl 2009, 48:5853-5855. 10.1002/anie.200900929, 19585625.
22. Ali JA, Jackson AP, Howells AJ, Maxwell A. The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs. Biochemistry 1993, 32:2717-2724. 10.1021/bi00061a033, 8383523.
23. Yang H, Murthy S, Sarkar FH, Sheng S, Reddy GP, Dou QP. Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. J Cell Physiol 2008, 217:569-576. 10.1002/jcp.21565, 2597227, 18726991.
24. Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D, Ralston SH. Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther 2009, 8:2339-2347. 10.1158/1535-7163.MCT-09-0133, 19671767.
25. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993, 7:812-821. 10.1101/gad.7.5.812, 8491378.
26. Lazarov M, Kubo Y, Cai T, Dajee M, Tarutani M, Lin Q, Fang M, Tao S, Green CL, Khavari PA. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 2002, 8:1105-1114. 10.1038/nm779, 12357246.
27. Mahale S, Aubry C, James Wilson A, Jenkins PR, Marechal JD, Sutcliffe MJ, Chaudhuri B. CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation. Bioorg Med Chem Lett 2006, 16:4272-4278. 10.1016/j.bmcl.2006.05.065, 16750360.
28. Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D. Characterization of celastrol to inhibit HSP90 and CDC37 interaction. J Biol Chem 2009, 18:35381-35389.
29. Kim Y, Kim K, Lee H, Han S, Lee YS, Choe J, Kim YM, Hahn JH, Ro JY, Jeoung D. Celastrol binds to ERK and inhibits FcepsilonRI signaling to exert an anti-allergic effect. Eur J Pharmacol 2009, 612:131-142. 10.1016/j.ejphar.2009.03.071, 19356729.
30. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996, 271:20608-20616. 10.1074/jbc.271.34.20608, 8702807.
31. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999, 19:2690-2698. 84062, 10082535.
32. Friedrichsen BN, Neubauer N, Lee YC, Gram VK, Blume N, Petersen JS, Nielsen JH, Moldrup A. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 2006, 188:481-492. 10.1677/joe.1.06160, 16522728.
33. Zhang DH, Marconi A, Xu LM, Yang CX, Sun GW, Feng XL, Ling CQ, Qin WZ, Uzan G, d'Alessio P. Tripterine inhibits the expression of adhesion molecules in activated endothelial cells. J Leukoc Biol 2006, 80:309-319. 10.1189/jlb.1005611, 16769766.
34. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, Hong YS, Lee JJ. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 2006, 72:1311-1321. 10.1016/j.bcp.2006.08.014, 16984800.
35. Huang FC, Chan WK, Moriarty KJ, Zhang DC, Chang MN, He W, Yu KT, Zilberstein A. Novel cytokine release inhibitors. Part I: Triterpenes. Bioorg Med Chem Lett 1998, 8:1883-1886. 10.1016/S0960-894X(98)00331-X, 9873452.
36. Zhang Q, Tsukahara F, Maru Y. N-acetyl-cysteine enhances growth in BCR-ABL-transformed cells. Cancer Sci 2005, 96:240-244. 10.1111/j.1349-7006.2005.00038.x, 15819723.
37. Martinez-Ruiz A, Villanueva L, Gonzalez de Orduna C, Lopez-Ferrer D, Higueras MA, Tarin C, Rodriguez-Crespo I, Vazquez J, Lamas S. S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc Natl Acad Sci USA 2005, 102:8525-8530. 10.1073/pnas.0407294102, 1150803, 15937123.
38. Wang J, Gines S, MacDonald ME, Gusella JF. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci 2005, 6:1. 10.1186/1471-2202-6-1, 548150, 15649316.
39. Morita H, Hirasawa Y, Muto A, Yoshida T, Sekita S, Shirota O. Antimitotic quinoid triterpenes from Maytenus chuchuhuasca. Bioorg Med Chem Lett 2008, 18:1050-1052. 10.1016/j.bmcl.2007.12.016, 18164197.